NASA now officially has no plans to use new mobile launcher for Artemis

NASA has removed the Exploration Upper Stage and Mobile Launcher 2 (ML2) from the near‑term Artemis roadmap, keeping the Space Launch System in its Block 1 configuration on Mobile Launcher 1 for the first three missions. ML2 — reported 90% complete, originally a $383 million Bechtel contract that the OIG says has swelled to >$1 billion with delivery pushed to late‑2026 — is unlikely to be used; the program’s cumulative costs have topped $100 billion, NASA is reassessing second‑stage options, and major contractors (Bechtel, Lockheed Martin, Boeing) must refocus schedules to meet the revised cadence (Artemis II as soon as April 1, Artemis III mid‑2027, IV/V in 2028).

Analysis

Market structure: Cancellation of ML2/EUS reduces addressable near-term revenue for specialty contractors tied to Block 1B hardware (direct loser: Boeing exposure to SLS variants; indirect: Bechtel faces contract/cashflow negotiation). Winners are firms that can scale standardized Block 1 production or provide commercial heavy‑lift (SpaceX/commercial suppliers); NASA’s 10‑month cadence target shifts value to volume/capex‑efficient producers and away from bespoke engineering work, compressing pricing power for high‑cost primes.

Risk assessment: Tail risks include a congressional funding cut or legal/IG-driven writedowns (ML2 was ~$383M → >$1B; program >$100B) that could create multi‑quarter revenue misses for primes. Near term (days–weeks): Artemis II outcome (target Apr 1) can spike vol; short term (3–9 months): RFP for replacement second stage and appropriations hearings; long term (1–3 years): potential pivot of work to commercial vendors (Starship) that can strand prime assets.

Trade implications: Expect front‑loaded volatility around Artemis II and the next 3–6 month RFP cadence. Favor tactical downside on Boeing (BA) via puts; selective convex long in Lockheed (LMT) via call spreads for stable defense/Orion cashflows. Consider contingent re‑allocation to Northrop (NOC) or Rocket Lab (RKLB) if RFP winners shift work away from BA/LMT.

Contrarian angles: Consensus understates salvage value of a 90%‑complete ML2 (NASA could take delivery or reconfigure, mitigating contractor write‑offs). Reaction may be overdone for primes with diversified backlog; history (Constellation rework) shows reallocation, not sector annihilation. Key unintended consequence: accelerating commercial incumbents’ negotiating leverage, leading to long‑run margin pressure on legacy primes.

Key Decisions for Investors

• Establish a 2.0–3.0% portfolio short position in BA via 6‑month puts 10–15% OTM (size to cost ~2% of portfolio). Rationale: concentrated SLS exposure, likely near‑term repricing; target ~15% downside in 3–9 months. Place stop‑loss if BA appreciation >10% or implied vol collapses >30% from entry.
• Buy a 1.5–2.0% long position in LMT using a 9–12 month 5% OTM call spread (debit) or outright shares if preferred. Rationale: diversified defense/Orion upside with less direct EUS exposure; target 8–12% upside by mid‑2027. Exit if LMT issues guidance cut >3% or loses >50% of anticipated NASA work in formal award announcements.
• Implement a conditional pair trade: long NOC (1.0% stock weight) and short BA (1.0% stock weight) only after NASA issues the RFP shortlist for the new second stage (expected within 3–6 months). Close positions after contract awards or 12 months; rationale: capture relative rerating if work reallocates to NOC/commercial winners.
• Within 30 days, reduce exposure to small/mid‑cap aerospace suppliers by 50% and redeploy 1.0–2.0% into commercial launch/scale beneficiaries (e.g., RKLB) and an aerospace ETF (ITA) as a hedge to commercial win scenarios. Reassess allocations 7 days after Artemis II (target Apr 1) and after any OIG/Congress budget decisions.